|

PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer

RECRUITINGPhase 2/3Sponsored by N.N. Alexandrov National Cancer Centre
Actively Recruiting
PhasePhase 2/3
SponsorN.N. Alexandrov National Cancer Centre
Started2025-07-01
Est. completion2033-06-30
Eligibility
Age18 Years – 75 Years
SexFEMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07472140

Summary

This is a randomized trial evaluating the results of using of PARP inhibitor combined with angiogenesis inhibitor. in patients with homologous recombination deficient primary ovarian cancer, fallopian-tube cancer, or primary peritoneal cancer of the III-IV stages.

Eligibility

Age: 18 Years – 75 YearsSex: FEMALEHealthy volunteers accepted
Inclusion Criteria:

* Age ≥18-≤75 years.
* Histologically confirmed diagnosis of serous or endometrioid high-grade ovarian cancer, fallopian-tube cancer or primary peritoneal cancer.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
* Possibility of performing diagnostic laparoscopy or cytoreductive surgery.
* Presence of homologous recombination deficiency (HRD).
* No contraindications to chemotherapy, or bevacizumab.
* Signed informed consent to participate in the study.

Exclusion Criteria:

* Presence of another active malignant invasive neoplasm.
* Pregnancy or lactation period.
* Disease progression during treatment.

Conditions4

CancerFallopian Tube CancersOvarian CancerPrimary Peritoneal Cancer

Interventions2

PARP inhibitorPARP inhibitor + Bevacizumab

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.